100 related articles for article (PubMed ID: 19773634)
1. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.
Read TR; Carey D; Mallon P; Mijch A; Goodall R; Hudson F; Wand H; Emery S
AIDS; 2009 Oct; 23(16):2222-3. PubMed ID: 19773634
[TBL] [Abstract][Full Text] [Related]
2. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.
van Luin M; Bannister WP; Mocroft A; Reiss P; Di Perri G; Peytavin G; Molto J; Karlson A; Castagna A; Beniowski M; Lundgren JD; Burger DM;
Antivir Ther; 2009; 14(1):75-83. PubMed ID: 19320239
[TBL] [Abstract][Full Text] [Related]
3. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
Gutiérrez F; Navarro A; Padilla S; Antón R; Masiá M; Borrás J; Martín-Hidalgo A
Clin Infect Dis; 2005 Dec; 41(11):1648-53. PubMed ID: 16267739
[TBL] [Abstract][Full Text] [Related]
4. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
Waters L; Fisher M; Winston A; Higgs C; Hadley W; Garvey L; Mandalia S; Perry N; Nicola M; Nelson M
AIDS; 2011 Jan; 25(1):65-71. PubMed ID: 21099666
[TBL] [Abstract][Full Text] [Related]
5. A randomized crossover study to compare efavirenz and etravirine treatment.
Nguyen A; Calmy A; Delhumeau C; Mercier IK; Cavassini M; Fayet-Mello A; Elzi L; Genné D; Rauch A; Bernasconi E; Hirschel B;
AIDS; 2011 Jan; 25(1):57-63. PubMed ID: 21076278
[TBL] [Abstract][Full Text] [Related]
6. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases.
Allavena C; Le Moal G; Michau C; Chiffoleau A; Raffi F
Antivir Ther; 2006; 11(2):263-5. PubMed ID: 16640107
[TBL] [Abstract][Full Text] [Related]
7. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.
Poeta J; Linden R; Antunes MV; Real L; Menezes AM; Ribeiro JP; Sprinz E
J Antimicrob Chemother; 2011 Nov; 66(11):2601-4. PubMed ID: 21890538
[TBL] [Abstract][Full Text] [Related]
8. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).
Nguyen A; Calmy A; Delhumeau C; Mercier I; Cavassini M; Mello AF; Elzi L; Rauch A; Bernasconi E; Schmid P; Hirschel B
AIDS; 2011 Jul; 25(12):1481-7. PubMed ID: 21593661
[TBL] [Abstract][Full Text] [Related]
9. No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART.
Takahashi M; Ibe S; Kudaka Y; Okumura N; Hirano A; Suzuki T; Mamiya N; Hamaguchi M; Kaneda T
AIDS Res Hum Retroviruses; 2007 Aug; 23(8):983-7. PubMed ID: 17725414
[TBL] [Abstract][Full Text] [Related]
10. Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects.
Mathiesen S; Justesen US; Von Lüttichau HR; Hansen AB
Scand J Infect Dis; 2006; 38(8):733-5. PubMed ID: 16857630
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
Leutscher PD; Stecher C; Storgaard M; Larsen CS
Scand J Infect Dis; 2013 Aug; 45(8):645-51. PubMed ID: 23427878
[TBL] [Abstract][Full Text] [Related]
12. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy.
Cabrera Figueroa S; Fernández de Gatta M; Hernández García L; Domínguez-Gil Hurlé A; Bustos Bernal C; Sepúlveda Correa R; García Sánchez MJ
Ther Drug Monit; 2010 Oct; 32(5):579-85. PubMed ID: 20720517
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
Aouri M; Barcelo C; Ternon B; Cavassini M; Anagnostopoulos A; Yerly S; Hugues H; Vernazza P; Günthard HF; Buclin T; Telenti A; Rotger M; Decosterd LA;
Drug Metab Dispos; 2016 Jan; 44(1):151-61. PubMed ID: 26553012
[TBL] [Abstract][Full Text] [Related]
14. Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials.
Ford N; Shubber Z; Pozniak A; Vitoria M; Doherty M; Kirby C; Calmy A
J Acquir Immune Defic Syndr; 2015 Aug; 69(4):422-9. PubMed ID: 25850607
[TBL] [Abstract][Full Text] [Related]
15. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.
Langmann P; Weissbrich B; Desch S; Väth T; Schirmer D; Zilly M; Klinker H
Eur J Med Res; 2002 Jul; 7(7):309-14. PubMed ID: 12176680
[TBL] [Abstract][Full Text] [Related]
16. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.
Pereira SA; Branco T; Caixas U; Côrte-Real RM; Germano I; Lampreia F; Monteiro EC
Ther Drug Monit; 2008 Feb; 30(1):60-6. PubMed ID: 18223464
[TBL] [Abstract][Full Text] [Related]
17. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
Nelson M; Stellbrink HJ; Podzamczer D; Banhegyi D; Gazzard B; Hill A; van Delft Y; Vingerhoets J; Stark T; Marks S
AIDS; 2011 Jan; 25(3):335-40. PubMed ID: 21150563
[TBL] [Abstract][Full Text] [Related]
18. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
[TBL] [Abstract][Full Text] [Related]
19. Impact of pharmacogenetics on CNS side effects related to efavirenz.
Sánchez Martín A; Cabrera Figueroa S; Cruz Guerrero R; Hurtado LP; Hurlé AD; Carracedo Álvarez A
Pharmacogenomics; 2013 Jul; 14(10):1167-78. PubMed ID: 23859571
[TBL] [Abstract][Full Text] [Related]
20. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.
Wintergerst U; Hoffmann F; Jansson A; Notheis G; Huss K; Kurowski M; Burger D
J Antimicrob Chemother; 2008 Jun; 61(6):1336-9. PubMed ID: 18343800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
